Hypoxia-driven selection of the metastatic phenotype

Intratumoral hypoxia is an independent indicator of poor patient outcome and increasing evidence supports a role for hypoxia in the development of metastatic disease. Studies suggest that the acquisition of the metastatic phenotype is not simply the result of dysregulated signal transduction pathways, but instead is achieved through a stepwise selection process driven by hypoxia. Hypoxia facilitates disruption of tissue integrity through repression of E-cadherin expression, with concomitant gain of N-cadherin expression which allows cells to escape anoikis. Through upregulation of urokinase-type plasminogen activator receptor (uPAR) expression, hypoxia enhances proteolytic activity at the invasive front and alters the interactions between integrins and components of the extracellular matrix, thereby enabling cellular invasion through the basement membrane and the underlying stroma. Cell motility is increased through hypoxia-induced hepatocyte growth factor (HGF)-MET receptor signaling, resulting in cell migration towards the blood or lymphatic microcirculation. Hypoxia-induced vascular endothelial growth factor (VEGF) activity also plays a critical role in the dynamic tumor–stromal interactions required for the subsequent stages of metastasis. VEGF promotes angiogenesis and lymphangiogenesis in the primary tumor, providing the necessary routes for dissemination. VEGF-induced changes in vascular integrity and permeability promote both intravasation and extravasation, while VEGF-induced angiogenesis in the secondary tissue is essential for cell proliferation and establishment of metastatic lesions. Through regulation of these critical molecular targets, hypoxia promotes each step of the metastatic cascade and selects tumor cell populations that are able to escape the unfavorable microenvironment of the primary tumor.

[1]  Michael V. Doyle,et al.  Regulation of Integrin Function by the Urokinase Receptor , 1996, Science.

[2]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[3]  R. Khokha,et al.  Steps in tumor metastasis: new concepts from intravital videomicroscopy , 1995, Cancer and Metastasis Reviews.

[4]  G. Semenza,et al.  V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. , 1997, Cancer research.

[5]  R. Hill,et al.  Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Toi,et al.  Quantitative analysis of vascular endothelial growth factor in primary breast cancer , 1996, Cancer.

[7]  J. Herman,et al.  Methylation Patterns of the E-cadherin 5′ CpG Island Are Unstable and Reflect the Dynamic, Heterogeneous Loss of E-cadherin Expression during Metastatic Progression* , 2000, The Journal of Biological Chemistry.

[8]  M. Goldberg,et al.  Inhibition of Hypoxia-inducible Factor 1 Activation by Carbon Monoxide and Nitric Oxide , 1999, The Journal of Biological Chemistry.

[9]  L. Trusolino,et al.  Scatter-factor and semaphorin receptors: cell signalling for invasive growth , 2002, Nature Reviews Cancer.

[10]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[11]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[12]  G. Semenza,et al.  Carbon Monoxide and Nitric Oxide Suppress the Hypoxic Induction of Vascular Endothelial Growth Factor Gene via the 5′ Enhancer* , 1998, The Journal of Biological Chemistry.

[13]  R. Khokha,et al.  Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate. , 1995, Cancer research.

[14]  R. Khokha,et al.  Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. , 1994, Cancer research.

[15]  F. Eschwège,et al.  Intratumoral oxygen tension in metastatic melanoma , 1997, Melanoma research.

[16]  Rakesh K Jain,et al.  Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics , 2002, Science.

[17]  L. Tacchini,et al.  Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. , 2001, Carcinogenesis.

[18]  N. Mackman,et al.  Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. , 1996, The Journal of biological chemistry.

[19]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[20]  R. Hill,et al.  Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. , 2001, Cancer research.

[21]  J. R. Kim,et al.  Involvement of MAPK pathway in hypoxia-induced up-regulation of urokinase plasminogen activator receptor in a human prostatic cancer cell line, PC3MLN4. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Leung,et al.  Vascular endothelial growth factor is up‐regulated in the early pre‐malignant stage of colorectal tumour progression , 1999, International journal of cancer.

[23]  A. Bosserhoff,et al.  Loss of E-cadherin leads to upregulation of NFκB activity in malignant melanoma , 2004, Oncogene.

[24]  C. Graham,et al.  Nitric oxide signalling and cellular adaptations to changes in oxygenation. , 2005, Toxicology.

[25]  S. Macdonald-Goodfellow,et al.  Hypoxia‐mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression , 1999, International journal of cancer.

[26]  J. Caro,et al.  Hypoxia regulatory elements of the human vascular endothelial growth factor gene. , 1994, Cellular & molecular biology research.

[27]  L. Liotta,et al.  Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. , 1974, Cancer research.

[28]  M. Shin,et al.  Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[29]  W. Birchmeier,et al.  Role of morphogenetic factors in metastasis of mammary carcinoma cells , 1998, Oncogene.

[30]  A. Bosserhoff,et al.  Expression of Dickkopf genes is strongly reduced in malignant melanoma , 2006, Oncogene.

[31]  R. Jain,et al.  Lack of general correlation between interstitial fluid pressure and oxygen partial pressure in solid tumors. , 1995, Microvascular research.

[32]  G. Semenza,et al.  Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. , 2003, Cancer research.

[33]  R. Hill,et al.  Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion , 2004, Clinical & Experimental Metastasis.

[34]  G. Christofori,et al.  Hepatocyte growth factor induces cell scattering through MAPK/Egr‐1‐mediated upregulation of Snail , 2006, The EMBO journal.

[35]  T. Ohtsuka,et al.  Tumor–stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c‐Met pathway , 2006, International journal of cancer.

[36]  A. Fyles,et al.  Long-term performance of interstial fluid pressure and hypoxia as prognostic factors in cervix cancer. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  T. E. Fitzpatrick,et al.  Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway. , 1998, Blood.

[38]  M. Tsao,et al.  Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. , 1992, Oncogene.

[39]  A. Harris,et al.  Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[40]  N. Mackman,et al.  Requirement of Receptor-bound Urokinase-type Plasminogen Activator for Integrin αvβ5-directed Cell Migration* , 1996, The Journal of Biological Chemistry.

[41]  L. Chung,et al.  Hypoxia increases VEGF-A production by prostate cancer and bone marrow stromal cells and initiates paracrine activation of bone marrow endothelial cells , 2006, Clinical & Experimental Metastasis.

[42]  Hadassa Degani,et al.  High-resolution magnetic resonance imaging of disparities in the transcapillary transfer rates in orthotopically inoculated invasive breast tumors. , 2004, Cancer research.

[43]  J. D. Chapman,et al.  Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age , 2000, Cancer.

[44]  D. Chung,et al.  Hypoxia-Inducible Factor-1-Independent Regulation of Vascular Endothelial Growth Factor by Hypoxia in Colon Cancer , 2004, Cancer Research.

[45]  H. Kuwano,et al.  Autocrine Motility Factor Signaling Enhances Pancreatic Cancer Metastasis , 2004, Clinical Cancer Research.

[46]  R. Hill,et al.  Effects of reoxygenation on cells from hypoxic regions of solid tumors: anticancer drug sensitivity and metastatic potential. , 1990, Journal of the National Cancer Institute.

[47]  K Satyamoorthy,et al.  N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. , 2001, Cancer research.

[48]  P. Russell,et al.  Urokinase‐type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer‐specific survival and potential therapeutic targets , 2000, International journal of cancer.

[49]  S. Eccles,et al.  Phosphoinositide 3-Kinase Signalling Pathways in Tumor Progression, Invasion and Angiogenesis , 2004, Tumori.

[50]  K. Tsukinoki,et al.  Hepatocyte growth factor and c-Met immunoreactivity are associated with metastasis in high grade salivary gland carcinoma. , 2004, Oncology reports.

[51]  A. Pasquini,et al.  Increased expression of Met protein is associated with up‐regulation of hypoxia inducible factor‐1 (HIF‐1) in tumour cells in papillary carcinoma of the thyroid , 2004, The Journal of pathology.

[52]  M. Simon Mitochondrial reactive oxygen species are required for hypoxic HIF alpha stabilization. , 2006, Advances in experimental medicine and biology.

[53]  H. Kobayashi,et al.  Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. , 1994, Cancer research.

[54]  G. Semenza,et al.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.

[55]  Mariann Bienz,et al.  β-Catenin: A Pivot between Cell Adhesion and Wnt Signalling , 2005, Current Biology.

[56]  A. Mercurio,et al.  The epithelial-mesenchymal tansition (EMT) and colorectal cancer progression , 2005, Cancer biology & therapy.

[57]  R. Jain,et al.  Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. , 2000, Cancer research.

[58]  Helen H. W. Chen,et al.  Hypoxia-inducible factor-1α correlates with MET and metastasis in node-negative breast cancer , 2007, Breast Cancer Research and Treatment.

[59]  D. Mottet,et al.  HIF‐1 and AP‐1 Cooperate to Increase Gene Expression in Hypoxia: Role of MAP Kinases , 2001, IUBMB life.

[60]  H. Beug,et al.  Epithelial-Mesenchymal Transition: NF-κB Takes Center Stage , 2004 .

[61]  I. Macdonald,et al.  Clinical targets for anti-metastasis therapy. , 2000, Advances in cancer research.

[62]  Rakesh K. Jain,et al.  Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.

[63]  L. Tacchini,et al.  Hepatocyte growth factor signaling regulates transactivation of genes belonging to the plasminogen activation system via hypoxia inducible factor-1. , 2003, Experimental cell research.

[64]  M. Oya,et al.  Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. , 2007, Carcinogenesis.

[65]  M. Simon Mitochondrial Reactive Oxygen Species are Required for Hypoxic HIFα Stabilization , 2006 .

[66]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[67]  R. Jain The next frontier of molecular medicine: Delivery of therapeutics , 1998, Nature Medicine.

[68]  P. Schumacker,et al.  Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia , 2006, Experimental physiology.

[69]  Y. Nakamura,et al.  Cloning, expression and mapping of a novel human zinc-finger gene TCF17 homologous to rodent Kid1. , 1997, Cytogenetics and cell genetics.

[70]  K. Karube,et al.  Prognostic significance of hepatocyte growth factor and c‐MET expression in patients with diffuse large B‐cell lymphoma , 2004, British journal of haematology.

[71]  E. Rofstad,et al.  Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. , 2002, Cancer research.

[72]  M. Pierotti,et al.  Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. , 1992, Oncogene.

[73]  D. He,et al.  Hypoxia-inducible factor-1alpha induces the epithelial-mesenchymal transition of human prostatecancer cells. , 2006, Chinese medical journal.

[74]  Eamonn R. Maher,et al.  Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein* , 2000, The Journal of Biological Chemistry.

[75]  H. Beug,et al.  Epithelial-mesenchymal transition: NF-kappaB takes center stage. , 2004, Cell cycle.

[76]  E. Rofstad,et al.  Pulmonary and lymph node metastasis is associated with primary tumor interstitial fluid pressure in human melanoma xenografts. , 2002, Cancer research.

[77]  M Ancukiewicz,et al.  Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. , 2000, Cancer research.

[78]  M. Nieto,et al.  The Snail genes as inducers of cell movement and survival: implications in development and cancer , 2005, Development.

[79]  L. Ellis,et al.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. , 1995, Cancer research.

[80]  N. Weidner,et al.  Tumor angiogenesis: review of current applications in tumor prognostication. , 1993, Seminars in diagnostic pathology.

[81]  M. Dellian,et al.  Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factoryvascular permeability factor antibody (angiogenesisyvascular obstruction) , 1996 .

[82]  C. Graham,et al.  Nitric oxide‐mediated regulation of hypoxia‐induced B16F10 melanoma metastasis , 2004, International journal of cancer.

[83]  S. Nathanson,et al.  Insights into the mechanisms of lymph node metastasis , 2003, Cancer.

[84]  R. Klausner,et al.  The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells , 1999, Molecular and Cellular Biology.

[85]  W. Kaelin,et al.  The von Hippel-Lindau tumor suppressor gene. , 2001, Experimental cell research.

[86]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[87]  F. Jänicke,et al.  Urokinase gene expression indicates early invasive growth in squamous cell lesions of the uterine cervix , 1999, The Journal of pathology.

[88]  A. Hanlon,et al.  Hypoxic regions exist in human prostate carcinoma. , 1999, Urology.

[89]  O. Melnyk,et al.  Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. , 1996, Cancer research.

[90]  S. Dower,et al.  Response of tumour cells to hypoxia: role of p53 and NFkB. , 1998, Molecular pathology : MP.

[91]  M. Goldberg,et al.  Post-transcriptional Regulation of Vascular Endothelial Growth Factor by Hypoxia (*) , 1996, The Journal of Biological Chemistry.

[92]  F. Spagnoli,et al.  Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes , 1997, The EMBO journal.

[93]  Vyacheslav Kalchenko,et al.  Real-time imaging of lymphogenic metastasis in orthotopic human breast cancer. , 2006, Cancer research.

[94]  J. Alexander,et al.  Vascular Permeability Factor/Vascular Endothelial Cell Growth Factor-mediated Permeability Occurs through Disorganization of Endothelial Junctional Proteins* , 1998, The Journal of Biological Chemistry.

[95]  K. Webster,et al.  Molecular Regulation of the Endothelin-1 Gene by Hypoxia , 2001, The Journal of Biological Chemistry.

[96]  T. Danielsen,et al.  Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis , 1999, British Journal of Cancer.

[97]  T. Nikaido,et al.  Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. , 2003, The American journal of pathology.

[98]  M. Norris,et al.  Hypoxia-induced Protein Binding to O2-responsive Sequences on the Tyrosine Hydroxylase Gene (*) , 1995, The Journal of Biological Chemistry.

[99]  J. Pouysségur,et al.  p42/p44 Mitogen-activated Protein Kinases Phosphorylate Hypoxia-inducible Factor 1α (HIF-1α) and Enhance the Transcriptional Activity of HIF-1* , 1999, The Journal of Biological Chemistry.

[100]  H. Pehamberger,et al.  NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. , 2004, The Journal of clinical investigation.

[101]  Richard D Klausner,et al.  The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. , 2002, Cancer cell.

[102]  B. Nordlinger,et al.  Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[103]  S. Oh,et al.  uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line , 2006, Cell Research.

[104]  A. Maity,et al.  Both increased stability and transcription contribute to the induction of the urokinase plasminogen activator receptor (uPAR) message by hypoxia. , 2000, Experimental cell research.

[105]  P. Vaupel,et al.  Hypoxic cervical cancers with low apoptotic index are highly aggressive. , 1999, Cancer research.

[106]  E. Rimm,et al.  Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma , 1999, Cancer.

[107]  F. Galimi,et al.  Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF. , 1994, The Journal of biological chemistry.

[108]  K. Nakashiro,et al.  Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. , 2006, Oral oncology.

[109]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. , 1999, Current topics in microbiology and immunology.

[110]  R. Reed,et al.  Inhibition of carcinoma cell‐derived VEGF reduces inflammatory characteristics in xenograft carcinoma , 2006, International journal of cancer.

[111]  I. Macdonald,et al.  Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth , 1994, Clinical & Experimental Metastasis.

[112]  D. Peet,et al.  Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch , 2002, Science.

[113]  Tae-Hee Lee,et al.  Vascular Endothelial Growth Factor Modulates the Transendothelial Migration of MDA-MB-231 Breast Cancer Cells through Regulation of Brain Microvascular Endothelial Cell Permeability* , 2003, The Journal of Biological Chemistry.

[114]  P. Gullino,et al.  Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. , 1975, Cancer research.

[115]  M. Oya,et al.  Renal cancer cells lacking hypoxia inducible factor (HIF)-1α expression maintain vascular endothelial growth factor expression through HIF-2α , 2006 .

[116]  R. Hill Tumor progression: Potential role of unstable genomic changes , 1990, Cancer and Metastasis Reviews.

[117]  C. Graham,et al.  Oxygen-mediated Regulation of Tumor Cell Invasiveness , 2002, The Journal of Biological Chemistry.

[118]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[119]  E. Rofstad,et al.  The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products. , 2005, Cancer research.

[120]  M. Dewhirst,et al.  Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. , 1996, Cancer research.

[121]  Y. Yuan,et al.  Responding to Hypoxia: Lessons From a Model Cell Line , 2002, Science's STKE.

[122]  E. Manseau,et al.  Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. , 1996, Cancer research.

[123]  M. Corada,et al.  Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. , 1998, Journal of cell science.

[124]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[125]  M. Goldberg,et al.  Transcriptional Regulation of the Rat Vascular Endothelial Growth Factor Gene by Hypoxia (*) , 1995, The Journal of Biological Chemistry.

[126]  Francisco Portillo,et al.  The transcription factor Snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression , 2000, Nature Cell Biology.

[127]  M. Dewhirst,et al.  Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.

[128]  M. Fiscella,et al.  The mutationally activated Met receptor mediates motility and metastasis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[129]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[130]  G. Semenza,et al.  Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. , 2000, Cancer.

[131]  H. Lyng,et al.  Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. , 1998, British Journal of Cancer.

[132]  G. Semenza Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[133]  Kiichi Hirota,et al.  Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. , 2005, Biochemical and biophysical research communications.

[134]  J. Brown,et al.  Exploiting tumour hypoxia in cancer treatment , 2004, Nature Reviews Cancer.

[135]  Andreas Sommer,et al.  NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression , 2004 .

[136]  G. Semenza,et al.  Expression of hypoxia‐inducible factor 1α in brain tumors , 2000 .

[137]  M. Makuuchi,et al.  Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. , 2000, Blood.

[138]  A. Bosserhoff,et al.  Influence of the cytoplasmic domain of E-cadherin on endogenous N-cadherin expression in malignant melanoma , 2006, Oncogene.

[139]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[140]  Jessica Lo,et al.  HIF‐1α is required for solid tumor formation and embryonic vascularization , 1998 .

[141]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[142]  H. Ryan,et al.  HIF-1 alpha is required for solid tumor formation and embryonic vascularization. , 1998, The EMBO journal.

[143]  R. Raval,et al.  Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. , 2006, Cancer research.

[144]  P. Comoglio,et al.  Hepatocyte growth factor is a pleiotropic factor protecting epithelial cells from apoptosis. , 1996, Cell death and differentiation.

[145]  L. Trusolino,et al.  HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[146]  D. Cheresh,et al.  Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis , 2004, The Journal of cell biology.

[147]  M. Duffy,et al.  Urokinase plasminogen activator: A prognostic marker in multiple types of cancer , 1999, Journal of surgical oncology.

[148]  P. Carmeliet,et al.  Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis (vol 394, pg 485, 1998) , 1998 .

[149]  O. Arrieta,et al.  Coexpression of hepatocyte growth factor/scatter factor (HGF/SF) and its receptor cMET predict recurrence of meningiomas. , 2004, Cancer letters.

[150]  E. Rimm,et al.  Expression of c‐met is a strong independent prognostic factor in breast carcinoma , 1998, Cancer.

[151]  F. Blasi,et al.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. , 1991, The American journal of pathology.

[152]  D. Waltz,et al.  Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. , 1994, The Journal of biological chemistry.

[153]  G. Semenza,et al.  Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. , 2006, Cancer research.

[154]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[155]  W. Risau,et al.  Activator-protein-1 binding potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. , 1997, The Biochemical journal.

[156]  Helen H. W. Chen,et al.  Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer. , 2007, Breast cancer research and treatment.

[157]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.

[158]  H. Höfler,et al.  Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy , 1997, Thrombosis and Haemostasis.

[159]  S. Bapat,et al.  Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. , 2005, Gynecologic oncology.

[160]  G. V. Vande Woude,et al.  Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[161]  M. Toi,et al.  Association of Vascular Endothelial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse in Primary Breast Cancer , 1994, Japanese journal of cancer research : Gann.